{"created":"2023-06-19T07:23:58.732549+00:00","id":9078,"links":{},"metadata":{"_buckets":{"deposit":"17a76ab3-5e51-47d1-ba2c-401d964193cd"},"_deposit":{"created_by":5,"id":"9078","owners":[5],"pid":{"revision_id":0,"type":"depid","value":"9078"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00009078","sets":["147:188"]},"author_link":["14084","14083","14085"],"item_1_alternative_title_5":{"attribute_name":"論文名よみ","attribute_value_mlt":[{"subitem_alternative_title":"〓"}]},"item_1_biblio_info_14":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1992-06-30","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"10","bibliographicPageStart":"1","bibliographicVolumeNumber":"41","bibliographic_titles":[{"bibliographic_title":"岐阜藥科大學紀要"},{"bibliographic_title":"The annual proceedings of Gifu College of Pharmacy","bibliographic_titleLang":"en"}]}]},"item_1_creator_6":{"attribute_name":"著者名(日)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"江田, 昭英"}],"nameIdentifiers":[{"nameIdentifier":"14083","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_7":{"attribute_name":"著者名よみ","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"コウダ, アキヒデ"}],"nameIdentifiers":[{"nameIdentifier":"14084","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_8":{"attribute_name":"著者名(英)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"KODA, AKIHIDE","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"14085","nameIdentifierScheme":"WEKO"}]}]},"item_1_description_1":{"attribute_name":"ページ属性","attribute_value_mlt":[{"subitem_description":"P(論文)","subitem_description_type":"Other"}]},"item_1_description_11":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_description":"喘息, アレルギー性鼻炎, アトピー性皮膚炎などのアトピー性疾患はCoombs and Gellの分類によるI型アレルギー反応によってひき起こされる。I型アレルギー反応は以下の3 stageに分類される。1st stageではマクロファージ, T cell, B cellなどの免疫担当細胞によって抗原に対するIgE抗体が産生され, IgE抗体はmast cellやbasophilに結合する。2nd stageは抗原抗体反応によるmast cellやbasophilの脱顆粒やchemical mediatorの遊離である。最終の3rd stageは遊離mediatorによるアレルギー症状の発現である。アトピー性疾患に対する薬物は1940年頃から3rd stageに作用するものが用いられるようになり, 現在では2nd stageに作用する薬物が効果的に用いられている。1st stageに作用する薬物もやがて用いられるようになるものと思われる。我々は各stageに作用するすぐれた薬物を見出すための研究を行ってきた。ここでは2nd stageに作用する薬物(baicaleinとtranilast)および1st stageに作用する薬物(alkyl glycosideとIPD-1151T)について述べた。これらのうちのいくつかはアトピー性疾患の治療に寄与している。","subitem_description_type":"Other"}]},"item_1_description_12":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"Atopic diseases such as asthma, rhinitis and atopic dermatitis are caused by Type I allergic reaction classified by Coombs and Gell. Type I allergic reaction is divided into 3 stages. The 1st stage is IgE antibody formation by immunocompetent cells including macrophage, T cell and B cell against antigens, followed by fixation of the IgE antibody on mast cells or basophils. The 2nd stage is degranulation and chemical mediator release from mast cells or basophils induced by antigen-antibody reaction. Finally the 3rd stage is the expression of allergic symptoms caused by the mediators released. The drugs for atopic diseases has been applied on the 3rd stage since about 1940,and nowadays those acting on the 2nd stage are effectively used. The drugs on the 1st stage will soon be available.The author has studied to seek excellent remedies for each stage. In the present paper, the drugs on the 2nd stage (baicalein and tranilast) and on the 1st stage (alkyl glycoside and IPD-1151T) are discussed, and some of which have contributed the therapy of atopic diseases.","subitem_description_type":"Other"}]},"item_1_source_id_13":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AN00053514","subitem_source_identifier_type":"NCID"}]},"item_1_text_10":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Laboratory of Pharmacology, Gifu Pharmaceutical University"}]},"item_1_text_9":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_value":"岐阜薬科大学"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"1992-06-30"}],"displaytype":"detail","filename":"KJ00000072714.pdf","filesize":[{"value":"615.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"url":"https://gifu-pu.repo.nii.ac.jp/record/9078/files/KJ00000072714.pdf"},"version_id":"1ee80867-659e-4fd4-b017-61fb476ce9d4"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"<総説>アトピー性疾患の征服をめざして","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"<総説>アトピー性疾患の征服をめざして"},{"subitem_title":"<Review>Strategy for the Control of Atopic Diseases","subitem_title_language":"en"}]},"item_type_id":"1","owner":"5","path":["188"],"pubdate":{"attribute_name":"公開日","attribute_value":"1992-06-30"},"publish_date":"1992-06-30","publish_status":"0","recid":"9078","relation_version_is_last":true,"title":["<総説>アトピー性疾患の征服をめざして"],"weko_creator_id":"5","weko_shared_id":-1},"updated":"2023-06-19T09:06:57.653583+00:00"}